Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04991506 | A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 30 | — | — | Oct 15, 2021 | May 17, 2024 | Jun 23, 2025 | 1 | China |
Maximum Tolerated Dose (MTD) of ES102 in combination with JS001
The safety profile of ES102 in combination with JS001 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Recommended Phase 2 Dose (RP2D) of ES102 in combination with JS001
| Arm | Type | Description |
|---|---|---|
| Part 1 ES102 Escalation in combination with JS001 | EXPERIMENTAL | ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors. |
| Part 2 ES102 Expansion in combination with JS001 | EXPERIMENTAL | Subjects will be treated with ES102 at the RP2D in combination with JS001. |
| Name | Type | Description |
|---|---|---|
| ES102 | DRUG | The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4) |
| JS001 | DRUG | JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle. |
Inclusion Criteria: * 1.Males or females aged ≥18 years. * 2.Ability to understand and the willingness to sign a written informed consent form. * 3.Subjects with pathological or cytological diagnosed advanced solid tumor, whose disease has progressed despite standard therapies, or for whom no furth...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |